News and Events
Beacon Biomedical Inc.completed its non-clinical and clinical studies for BeScreened™-CRC and receives its CLIA approval for clinical use as a blood-based colorectal screening test for screening non-compliant patients. The test is 95% accurate and is now available to the public through partnered ACOs and Independent Physicians Offices.
March is Colorectal Cancer (CRC) Awareness Month. Be Aware, Be Prepared & Get Screened for CRC.
Beacon Biomedical Inc. receives its CLIA Laboratory ID (Number 03D2122615) from the Centers for Medicare & Medicaid Services, effective as of December 1, 2016
Beacon Biomedical Inc. and Sonora Quest Laboratories (SQL) have executed a Laboratory Draw Agreement giving Beacon access to all of SQL's Arizona-based Patient Service Centers and In-Office Phlebotomy locations. Beacon's clients and their patients will be able to have blood drawn, processed and shipped to Beacon's CLIA Laboratory for testing. This contract is in advance to Beacon's imminent market launch of its blood test for colorectal cancer screening, BeScreened-CRC.
Beacon Biomedical Inc. Appoints Industry Veteran to Lead Cancer Screening Technology Commercialization.
Beacon Biomedical Inc. moves to new corporate offices and announces the opening of its new R&D and CLIA laboratory facilities.
Beacon Biomedical Inc. to Present at Singular Research Spring Select "Best of the Uncovereds" Investment Conference on June 9, 2016
Beacon Biomedical Inc. to Exhibit at BIO International Conference in San Francisco on June 6-9, 2016
Beacon Biomedical Inc. Appoints Industry Veteran To Lead Commercialization. Dave English had been appointed as Director of Business Development.
Congratulations to Beacon Biomedical! They were named as 1 of the 6 winners in the Arizona Commerce Authority’s Fall 2015 round of the Arizona Innovation Challenge
Listen to Beacon Biomedical's CEO talk about their colon cancer screening test, ColoRT™ at ehealth radio https://t.co/mOMkMIMbDk
Beacon Biomedical, Inc., a privately held company focused on developing patient friendly cancer screening announced that it received an investment from Hyalescent Ventures.
Beacon advances to the Semi-Finalist Round of the Arizona Commerce Authority's Fall 2015 Arizona Innovation Challenge as one of Top 25 Companies out of 131 applicants
Beacon has been awarded a Phase I SBIR Grant for "Easy, Affordable & Accurate Point of Care Screening to Reduce Colorectal Cancer Disparities" from the National Institute of Biomedical Imaging and Biomedical Engineering at the National Institutes of Health.
Easy, Accurate and Affordable Cancer Screening....Welcome to the Beacon Revolution!